Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that a new questionnaire to assess mental health in alopecia patients shows low rates of seeking mental health services and support groups.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

Many patients with Alopecia Areata in Korea experience anxiety, depression, and reduced quality of life, which are often unrelated to the severity of hair loss.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Higher inflammation markers are linked to more severe alopecia areata.

Multiparametric ultrasound is a useful non-invasive tool for assessing scalp conditions in alopecia areata patients.

The Egyptian Arabic Skindex-16 is a reliable way to measure how skin diseases affect quality of life in Egyptian patients.

Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.

Current treatments for Alopecia Areata don't fully meet patients' needs, indicating a need for better therapies.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

The Turkish version of the MAIA-2 Scale is valid and reliable for patients at a dermatology clinic.

Patients were very satisfied with the multidisciplinary group visit for alopecia areata.

People with alopecia areata often have higher rates of allergies and autoimmune diseases.

Higher antigliadin antibody levels are linked to alopecia areata severity.

A new classification and scoring system is needed for alopecia areata to better assess severity.

Androgenetic alopecia affects men's emotions more than symptoms or daily function.

Traumatic stress and alexithymia may contribute to alopecia areata.

People with Alopecia Areata are more likely to have autoimmune diseases, inflammatory diseases, and mental health issues like anxiety and depression.

Certain hair and scalp features indicate a worse outcome in alopecia areata.

AI can accurately measure hair loss severity in alopecia areata.

Portuguese WAA-QoL questionnaire validated; FPHL severity, schooling, and phototypes affect patients' quality of life.

Addressing psychosocial symptoms can improve outcomes for people with Hidradenitis Suppurativa.

Alopecia areata causes negative emotions and stress due to hair loss and emotional triggers.

Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.

Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.

Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Most patients with alopecia areata did not achieve lasting hair regrowth despite treatment.

Alopecia Areata affects both patients and their cohabitants' quality of life and emotional well-being.

Trichoscopy helps better understand and manage alopecia areata, improving patient outcomes.